ID   SBC-5
AC   CVCL_1679
SY   SBC5
DR   CLO; CLO_0037043
DR   EFO; EFO_0002855
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472516
DR   BioSample; SAMN10988207
DR   cancercelllines; CVCL_1679
DR   Cell_Model_Passport; SIDM00368
DR   CGH-DB; 95-1
DR   CGH-DB; 9050-4
DR   ChEMBL-Cells; CHEMBL3308493
DR   ChEMBL-Targets; CHEMBL614896
DR   Cosmic; 713880
DR   Cosmic; 801614
DR   Cosmic; 844823
DR   Cosmic; 876155
DR   Cosmic; 918017
DR   Cosmic; 929153
DR   Cosmic; 932946
DR   Cosmic; 1212201
DR   Cosmic; 1571747
DR   Cosmic; 1995624
DR   Cosmic; 2125287
DR   Cosmic; 2668344
DR   Cosmic-CLP; 713880
DR   DepMap; ACH-000670
DR   EGA; EGAS00001000978
DR   GDSC; 713880
DR   GEO; GSM17314
DR   GEO; GSM827566
DR   GEO; GSM887556
DR   GEO; GSM888639
DR   GEO; GSM986192
DR   GEO; GSM1670406
DR   IARC_TP53; 2387
DR   JCRB; JCRB0819
DR   LiGeA; CCLE_781
DR   LINCS_LDP; LCL-1821
DR   PharmacoDB; SBC5_1349_2019
DR   PRIDE; PXD011896
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1679
DR   PubChem_Cell_line; CVCL_1679
DR   Wikidata; Q54952179
RX   CelloPub=CLPUB00132;
RX   DOI=10.4044/joma1947.104.9-10_905;
RX   PubMed=8286010;
RX   PubMed=9290701;
RX   PubMed=9413215;
RX   PubMed=10358721;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=12107105;
RX   PubMed=15016488;
RX   PubMed=15185009;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22399608;
RX   PubMed=22460905;
RX   PubMed=23066953;
RX   PubMed=23381221;
RX   PubMed=25120651;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 24 hours (DOI=10.4044/joma1947.104.9-10_905); 31.6 hours (PubMed=8286010); ~40 hours (Note=Lot 111898), 21 hours (Note=Lot 08082007), ~21 hours (Note=Lot 09142018) (JCRB=JCRB0819).
CC   HLA typing: A*02:07,33:03; B*46:01,58:01; C*01:02,03:02; DQB1*06:07,06:07; DRB1*13:02,14:46 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 2901; DLG2; Unexplicit; Ex7-9del; Zygosity=Homozygous (PubMed=20215515).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=10536175; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.28%; Native American=0%; East Asian, North=78.17%; East Asian, South=20.72%; South Asian=0.15%; European, North=0.14%; European, South=0.54% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 8,10
ST   D16S539: 12
ST   D5S818: 10,11
ST   D7S820: 8,11
ST   TH01: 6
ST   TPOX: 9,12
ST   vWA: 14,18
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 38
//
RX   CelloPub=CLPUB00132;
RA   Kishimoto N., Ohnoshi T., Hiraki S., Miyake K., Ozawa S., Tamura T.,
RA   Numata K., Kawahara N., Tamura R., Miyamoto H., Nishii K., Kimura I.;
RT   "Establishment and characterization of five cell lines from human
RT   small cell carcinoma of the lung.";
RL   Nihon Haigan Gakkai 24:644-644(1984).
//
RX   DOI=10.4044/joma1947.104.9-10_905;
RA   Kishimoto N.;
RT   "Studies on cell biology and chemotherapy of lung cancer using tissue
RT   culture techniques. Part 2. Biological characteristics of five newly
RT   established small cell lung cancer cell lines.";
RL   Okayama Igakkai Zasshi 104:905-913(1992).
//
RX   PubMed=8286010;
RA   Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.;
RT   "Inhibitory effects of cholera toxin on in vitro growth of human lung
RT   cancer cell lines.";
RL   Anticancer Drug Des. 8:417-428(1993).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9413215;
RA   Yamane H., Kiura K., Tabata M., Bessho A., Tsuchida T., Motoda K.,
RA   Hiraki A., Ueoka H., Harada M.;
RT   "Small cell lung cancer can express CD34 antigen.";
RL   Anticancer Res. 17:3627-3632(1997).
//
RX   PubMed=10358721; DOI=10.18926/AMO/31626;
RA   Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K.,
RA   Kohara H., Harada M.;
RT   "Establishment of a drug sensitivity panel using human lung cancer
RT   cell lines.";
RL   Acta Med. Okayama 53:67-75(1999).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=12107105; DOI=10.1016/S0002-9440(10)64172-7;
RA   Yokoi S., Yasui K., Saito-Ohara F., Koshikawa K., Iizasa T.,
RA   Fujisawa T., Terasaki T., Horii A., Takahashi T., Hirohashi S.,
RA   Inazawa J.;
RT   "A novel target gene, SKP2, within the 5p13 amplicon that is
RT   frequently detected in small cell lung cancers.";
RL   Am. J. Pathol. 161:207-216(2002).
//
RX   PubMed=15016488; DOI=10.1016/S0140-6736(04)15693-6;
RA   Jones M.H., Virtanen C., Honjoh D., Miyoshi T., Satoh Y., Okumura S.,
RA   Nakagawa K., Nomura H., Ishikawa Y.;
RT   "Two prognostically significant subtypes of high-grade lung
RT   neuroendocrine tumours independent of small-cell and large-cell
RT   neuroendocrine carcinomas identified by gene expression profiles.";
RL   Lancet 363:775-781(2004).
//
RX   PubMed=15185009; DOI=10.1007/s00262-004-0533-9;
RA   Yamaji H., Iizasa T., Koh E., Suzuki M., Otsuji M., Chang H.,
RA   Motohashi S., Yokoi S., Hiroshima K., Tagawa M., Nakayama T.,
RA   Fujisawa T.;
RT   "Correlation between interleukin 6 production and tumor proliferation
RT   in non-small cell lung cancer.";
RL   Cancer Immunol. Immunother. 53:786-792(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22399608;
RA   Tsuchida T., Yamane H., Ochi N., Tabayashi T., Hiraki A., Nogami N.,
RA   Takigawa N., Kiura K., Tanimoto M.;
RT   "Cytotoxicity of activated natural killer cells and expression of
RT   adhesion molecules in small-cell lung cancer.";
RL   Anticancer Res. 32:887-892(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23066953; DOI=10.1111/cas.12045;
RA   Kubo T., Takigawa N., Osawa M., Harada D., Ninomiya T., Ochi N.,
RA   Ichihara E., Yamane H., Tanimoto M., Kiura K.;
RT   "Subpopulation of small-cell lung cancer cells expressing CD133 and
RT   CD87 show resistance to chemotherapy.";
RL   Cancer Sci. 104:78-84(2013).
//
RX   PubMed=23381221; DOI=10.3892/or.2013.2266;
RA   Suzuki M., Shiraishi K., Eguchi A., Ikeda K., Mori T., Yoshimoto K.,
RA   Ohba Y., Yamada T., Ito T., Baba Y., Baba H.;
RT   "Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small
RT   cell lung cancer.";
RL   Oncol. Rep. 29:1308-1314(2013).
//
RX   PubMed=25120651; DOI=10.3892/ol.2014.2234;
RA   Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K.,
RA   Shibata H., Ito T., Baba Y., Baba H.;
RT   "Aberrant methylation and silencing of IRF8 expression in non-small
RT   cell lung cancer.";
RL   Oncol. Lett. 8:1025-1030(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//